Abstract
Lividomycin (LVM) is a new aminoglycoside antibiotic produced in Japan.
It is active against Pseudomonas as well as other gram-negative bacteria. In vivo effect of LVM was evaluated by using experimental pyelonephritis in rabbit, comparing with kanamycin (KM) and gentamicin (GM).
Serum and urine levels of LVM were estimated in 2 rabbits receiving intramuscular dose of 100 mg/kg/body weight.The average serum level reached to a maximum of 26.5mcg/ml one hour after administration and was 19.25mcg/ml 5 hours later.
Urine level reached to peak of 820mcg/ml and 13,000mcg/ml in 2-4 hours.
Recovery from urine in 6 hours was 3.8 and 24%.
Twenty mg/kg/body weight of LVM and KM, and 1.6mg/kg/body weight of GM were intramuscularly administered by one shot or for 1 week after inoculation of Pseudomonas into renal pelvis. Animals were sacrificed on the 8th day.
Bacteriological studies of the kidney renal pelvic urine and bladder urine as well as histopathologic studies were performed.The in vivo effect against Pseudomonas in infected kidney was in the order of LVM≥GM>KM in the one-shot group, and GM>LVM>KM in the continuously administered group.
